High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma.
High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma.
复制标题
IMPDH2的高表达与原发性鼻咽癌的侵袭性特征和不良预后相关。
DOI：
10.1038/s41598-017-00887-1
复制
发表时间：
2017-04-07
影响因子：
4.6
通讯作者：
Zhang J
中科院分区：
文献类型：
--
作者：
Xu Y;Zheng Z;Gao Y;Duan S;Chen C;Rong J;Wang K;Yun M;Weng H;Ye S;Zhang J
肌苷单磷酸脱氢酶II型（IMPDH 2）已被证明在几种人类癌症的发展和进展中起关键作用。然而，IMPDH 2在鼻咽癌（NPC）中的表达及其临床意义知之甚少。采用Western blotting、qRT-PCR和免疫组织化学方法检测IMPDH 2在鼻咽癌细胞系和组织中的表达。在我们的研究中，在NPC细胞系中观察到IMPDH 2在蛋白和mRNA水平上的表达高于NPEC 2 Bmi-1。IMPDH 2蛋白在鼻咽癌组织中的表达明显高于癌旁组织。IMPDH 2的表达与鼻咽癌的T分期（P = 0.023）、TNM分期（P = 0.020）、远处转移（P = 0.001）和死亡（P = 0.002）有关。进一步的考克斯回归分析显示IMPDH 2表达是总生存期（P = 0.001）和无病生存期（P < 0.001）的独立预后因素。分层生存分析显示IMPDH 2高表达可能是影响鼻咽癌患者预后的因素，其中TNM分期I/II期（OS：P = 0.012; DMFS：P = 0.007），TNM分期III/IV期（OS：P = 0.028; DMFS：P = 0.020）。本研究提示IMPDH 2可能作为一种独立的鼻咽癌预后生物标志物，IMPDH高表达提示鼻咽癌患者预后不良。
Inosine monophosphate dehydrogenase type II (IMPDH2) has been shown to play critical roles in the development and progression of several human cancers. However, little is known about IMPDH2 expression and its clinical significance in nasopharyngeal carcinoma (NPC). Western blotting, qRT-PCR and immunohistochemistry were employed to evaluate IMPDH2 expression in NPC cell lines and tissues. In our study, elevated expression of IMPDH2 was observed at both the protein and mRNA levels in NPC cell lines than in NPEC2 Bmi-1. IMPDH2 protein expression was markedly higher in NPC tissues than in adjacent non-tumorous tissues. Moreover, IMPDH2 expression in NPC correlated with several clinicopathological parameters, including T classification (P = 0.023), TNM stage (P = 0.020), distant metastasis (P = 0.001) and death (P = 0.002). Further Cox regression analysis suggested that IMPDH2 expression was an independent prognostic factor for overall survival (P = 0.001) and disease-free survival (P < 0.001). In addition, stratified survival analysis showed that high expression of IMPDH2 could be a prognostic factor for NPC patients with TNM stage I/II (OS: P = 0.012; DMFS: P = 0.007), TNM stage III/IV (OS: P = 0.028; DMFS: P = 0.020). Our study demonstrates IMPDH2 may be served as an independent prognostic biomarker for NPC patients, in which high IMPDH expression suggests poor prognosis of NPC patients.